gPop | ID | ID vs gPop | ||
---|---|---|---|---|
n (%) | n (%) | RR (95% CI) | ||
Insulin-dependent diabetes mellitus | ||||
Insulins and analogues | Women | 57 (85) | 65 (83) | 0.98 (0.69–1.40) |
Men | 90 (84) | 90 (87) | 1.03 (0.77–1.38) | |
Men vs women | 0.99 (0.71–1.38) | 1.04 (0.76–1.43) | ||
Fast-acting | Women | 42 (63) | 30 (38) | 0.61 (0.38–0.98) |
Men | 61 (57) | 50 (48) | 0.84 (0.58–1.23) | |
Men vs women | 0.91 (0.61–1.35) | 1.25 (0.80–1.97) | ||
Intermediate-acting | Women | 24 (36) | 21 (27) | 0.75 (0.42–1.35) |
Men | 47 (44) | 36 (35) | 0.79 (0.51–1.22) | |
Men vs women | 1.23 (0.75–2.01) | 1.29 (0.75–2.20) | ||
Intermediate/long-acting comb. fast-acting | Women | 22 (33) | 42 (54) | 1.64 (0.98–2.75) |
Men | 30 (28) | 54 (52) | 1.85 (1.19–2.89) | |
Men vs women | 0.85 (0.49–1.48) | 0.96 (0.64–1.44) | ||
Long-acting | Women | 29 (43) | 25 (32) | 0.74 (0.43–1.26) |
Men | 36 (34) | 37 (36) | 1.06 (0.69–1.67) | |
Men vs women | 0.78 (0.48–1.27) | 1.11 (0.67–1.84) | ||
Blood glucose lowering drugs excl. Insulins | Women | 40 (60) | 52 (67) | 1.12 (0.74–1.69) |
Men | 56 (52) | 74 (71) | 1.36 (0.96–1.92) | |
Men vs women | 0.88 (0.58–1.32) | 1.07 (0.75–1.52) | ||
Biguanides | Women | 37 (55) | 46 (59) | 1.07 (0.69–1.65) |
Men | 54 (50) | 66 (63) | 1.26 (0.88–1.80) | |
Men vs women | 0.91 (0.60–1.39) | 1.08 (0.74–1.57) | ||
Sulfonylureas | Women | 13 (19) | 21 (27) | 1.39 (0.70–2.77) |
Men | 14 (13) | 34 (33) | 2.50 (1.34–4.66) | |
Men vs women | 0.67 (0.32–1.44) | 1.21 (0.71–2.09) | ||
Combinations | Women | 1 (1) | 2 (3) | NC |
Men | 3 (3) | 0 (0) | NC | |
Men vs women | NC | NC | ||
α glucosidase inhibitors | Women | 2 (3) | 3 (4) | NC |
Men | 1 (1) | 1 (1) | NC | |
Men vs women | NC | NC | ||
Thiazolidinediones | Women | 3 (4) | 0 (0) | NC |
Men | 2 (2) | 3 (3) | NC | |
Men vs women | NC | NC | ||
Dipeptidyl peptidase-4 inhibitors | Women | 3 (4) | 2 (3) | NC |
Men | 5 (5) | 0 (0) | NC | |
Men vs women | NC | NC | ||
Repaglinide or nateglinide | Women | 3 (4) | 4 (5) | NC |
Men | 7 (7) | 3 (3) | NC | |
Men vs women | NC | NC | ||
Exenatide or liraglutide | Women | 0 (0) | 1 (1) | NC |
Men | 1 (1) | 2 (2) | NC | |
Men vs women | NC | NC | ||
Non-insulin-dependent diabetes | ||||
Insulins and analogues | Women | 94 (51) | 161 (52) | 1.02 (0.79–1.32) |
Men | 158 (44) | 177 (50) | 1.14 (0.92–1.42) | |
Men vs women | 0.87 (0.67–1.12) | 0.97 (0.78–1.20) | ||
Fast-acting | Women | 53 (28) | 61 (20) | 0.69 (0.48–1.00) |
Men | 72 (20) | 75 (21) | 1.06 (0.77–1.47) | |
Men vs women | 0.70 (0.49–1.00) | 1.08 (0.77–1.52) | ||
Intermediate-acting | Women | 48 (26) | 68 (22) | 0.85 (0.59–1.23) |
Men | 83 (23) | 61 (17) | 0.75 (0.54–1.04) | |
Men vs women | 0.89 (0.63–1.28) | 0.79 (0.56–1.12) | ||
Intermediate/long-acting comb. fast-acting | Women | 44 (24) | 103 (33) | 1.40 (0.98–1.99) |
Men | 70 (19) | 109 (31) | 1.59 (1.18–2.14) | |
Men vs women | 0.82 (0.56–1.20) | 0.93 (0.71–1.22) | ||
Long-acting | Women | 36 (19) | 40 (13) | 0.67 (0.42–1.04) |
Men | 48 (13) | 60 (17) | 1.28 (0.87–1.86) | |
Men vs women | 0.69 (0.45–1.06) | 1.32 (0.89–1.97) | ||
Blood glucose lowering drugs excl. Insulins | Women | 138 (74) | 246 (79) | 1.07 (0.87–1.31) |
Men | 285 (79) | 282 (80) | 1.01 (0.86–1.19) | |
Men vs women | 1.07 (0.87–1.31) | 1.01 (0.85–1.20) | ||
Biguanides | Women | 127 (68) | 225 (72) | 1.06 (0.85–1.32) |
Men | 271 (75) | 248 (70) | 0.93 (0.79–1.11) | |
Men vs women | 1.10 (0.89–1.26) | 0.97 (0.81–1.16) | ||
Sulfonylureas | Women | 51 (27) | 105 (34) | 1.23 (0.88–1.72) |
Men | 99 (28) | 125 (35) | 1.29 (0.99–1.68) | |
Men vs women | 1.00 (0.72–1.41) | 1.05 (0.81–1.36) | ||
Combinations | Women | 7 (4) | 7 (2) | 0.60 (0.21–1.71) |
Men | 13 (4) | 4 (1) | NC | |
Men vs women | 0.96 (0.38–2.41) | NC | ||
α glucosidase inhibitors | Women | 4 (2) | 7 (2) | NC |
Men | 2 (1) | 1 (0) | NC | |
Men vs women | NC | NC | ||
Thiazolidinediones | Women | 7 (4) | 7 (2) | 0.60 (0.21–1.71) |
Men | 16 (4) | 14 (4) | 0.89 (0.44–1.83) | |
Men vs women | 1.18 (0.49–2.87) | 1.76 (0.71–4.37) | ||
Dipeptidyl peptidase-4 inhibitors | Women | 17 (9) | 13 (4) | 0.46 (0.22–0.94) |
Men | 25 (7) | 9 (3) | 0.36 (0.17–0.79) | |
Men vs women | 0.76 (0.41–1.41) | 0.61 (0.26–1.43) | ||
Repaglinide or nateglinide | Women | 11 (6) | 20 (6) | 1.09 (0.52–2.27) |
Men | 23 (6) | 16 (5) | 0.71 (0.38–1.34) | |
Men vs women | 1.08 (0.53–2.22) | 0.71 (0.37–1.36) | ||
Exenatide or liraglutide | Women | 3 (2) | 5 (2) | NC |
Men | 12 (3) | 2 (1) | NC | |
Men vs women | NC | NC | ||
Hypertension | ||||
Diuretics | Women | 307 (49) | 220 (61) | 1.26 (1.06–1.50) |
Men | 334 (39) | 262 (57) | 1.48 (1.26–1.74) | |
Men vs women | 0.80 (0.68–0.93) | 0.94 (0.78–1.12) | ||
Beta blocking agents | Women | 415 (66) | 216 (60) | 0.91 (0.78–1.08) |
Men | 538 (63) | 281 (62) | 0.98 (0.85–1.14) | |
Men vs women | 0.95 (0.84–1.08) | 1.02 (0.86–1.22) | ||
Calcium channel blockers | Women | 317 (50) | 148 (41) | 0.82 (0.68–1.00) |
Men | 475 (55) | 214 (47) | 0.85 (0.72–1.00) | |
Men vs women | 1.10 (0.95–1.27) | 1.14 (0.92–1.40) | ||
Agents acting on the renin-angiotensin system | Women | 455 (72) | 223 (62) | 0.86 (0.73–1.01) |
Men | 729 (85) | 320 (70) | 0.83 (0.72–0.94) | |
Men vs women | 1.18 (1.05–1.32) | 1.13 (0.95–1.34) | ||
ACE inhibitors | Women | 319 (51) | 189 (53) | 1.04 (0.87–1.25) |
Men | 544 (63) | 274 (60) | 0.95 (0.82–1.10) | |
Men vs women | 1.25 (1.09–1.44) | 1.14 (0.95–1.37) | ||
Angiotensin II antagonists | Women | 259 (41) | 60 (17) | 0.41 (0.31–0.54) |
Men | 355 (41) | 85 (19) | 0.45 (0.36–0.57) | |
Men vs women | 1.01 (0.86–1.18) | 1.11 (0.80–1.55) |